Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BLTE

Belite Bio Inc ADR

Oct 22 • 04:00PM ET

89.36

-2.64 -2.87 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB GILD MRNA BMY AMGN PFE LLY ABBV

| Held by: SPEM ONEQ BBC APIE GXC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.55	Insider Own	-	Shs Outstand	32.60M	Perf Week	9.97%
Market Cap	2.91B	Forward P/E	-	EPS next Y	-1.57	Insider Trans	-	Shs Float	-	Perf Month	25.77%
Enterprise Value	2.76B	PEG	-	EPS next Q	-0.49	Inst Own	0.74%	Short Float	-	Perf Quarter	44.48%
Income	-49.38M	P/S	-	EPS this Y	-62.50%	Inst Trans	-0.91%	Short Ratio	4.46	Perf Half Y	51.97%
Sales	0.00M	P/B	19.44	EPS next Y	18.12%	ROA	-35.93%	Short Interest	0.24M	Perf YTD	41.62%
Book/sh	4.60	P/C	19.53	EPS next 5Y	52.68%	ROE	-37.34%	52W High	92.11 -2.99%	Perf Year	56.91%
Cash/sh	4.58	P/FCF	-	EPS past 3/5Y	-43.42% -777.09%	ROIC	-32.94%	52W Low	49.00 82.37%	Perf 3Y	217.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.24% 4.04%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-26.26%	Oper. Margin	-	ATR (14)	3.44	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	24.31	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	72.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.31	EPS Q/Q	-59.95%	SMA20	12.38%	Beta	-1.48	Target Price	93.25
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	24.21%	Rel Volume	1.04	Prev Close	92.00
Employees	25	LT Debt/Eq	0.00	Earnings	Aug 11 BMO	SMA200	39.90%	Avg Volume	52.77K	Price	89.36
IPO	Apr 29, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	-21.95% -	Trades		Volume	54,787	Change	-2.87%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Maxim Group	Buy	$60
Jul-28-23	Initiated	Cantor Fitzgerald	Overweight	$43
Jul-26-23	Initiated	SVB Securities	Outperform	$25
Aug-01-22	Initiated	H.C. Wainwright	Buy	$58
Jul-01-22	Initiated	The Benchmark Company	Buy	$57

Oct-16-25 08:00AM	Belite Bio to Participate in the 2025 Maxim Growth Summit (GlobeNewswire) +9.61%
Oct-15-25 08:00AM	Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant (GlobeNewswire)
Oct-02-25 08:18AM	3 Lesser-Known Healthcare Names With Major Upside in Store (MarketBeat)
Sep-15-25 05:17AM	Belite Bio wraps up Phase III trial of Stargardt disease treatment (Clinical Trials Arena)
Sep-12-25 08:00AM	Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease (GlobeNewswire)
08:00AM	Loading…
Sep-08-25 08:00AM	Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors (GlobeNewswire)
Aug-27-25 08:00AM	Belite Bio to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 03:07AM	Belite Bio Inc (BLTE) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Aug-11-25 06:00AM	Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-07-25 08:00AM	Belite Bio Announces Registered Direct Offering of $15 Million (GlobeNewswire)
Aug-06-25 08:00AM	Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-04-25 08:38AM	New Strong Sell Stocks for August 4th (Zacks) +6.19%
08:00AM	Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-23-25 08:00AM	Belite Bio to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-22-25 06:16AM	New Strong Sell Stocks for July 22nd (Zacks)
12:01PM	Loading…
Jul-03-25 12:01PM	Enrolment concludes in Belite Bios trial of Tinlarebant for geographic atrophy (Clinical Trials Arena)
Jul-02-25 03:00AM	Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy (GlobeNewswire)
May-21-25 03:00AM	Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
May-16-25 08:35AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
May-15-25 07:01PM	Belite Bio Inc (BLTE) Q1 2025 Earnings Call Highlights: Strong Financial Position Amid Rising ... (GuruFocus.com) +8.88%
May-13-25 09:00PM	Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
03:00AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
May-12-25 08:00PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
08:35AM	Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th (GlobeNewswire)
08:00AM	Belite Bio to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
May-08-25 10:44AM	UPDATE - International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
08:35AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
May-07-25 08:00AM	Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 08:00AM	Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 06:00AM	Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
06:00AM	Loading…
06:00AM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire)
Mar-11-25 03:00AM	Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-04-25 08:00AM	Belite Bio to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-27-25 02:00AM	Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects (GlobeNewswire)
Feb-05-25 10:35PM	Belite Bio Announces Registered Direct Offering of $15 Million (GlobeNewswire)
Nov-27-24 03:00AM	Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 (GlobeNewswire) +5.34%
Nov-12-24 01:00AM	Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-05-24 08:00AM	Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-03-24 04:00PM	Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds (GlobeNewswire)
Oct-14-24 08:00AM	Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Oct-08-24 08:00AM	Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit (GlobeNewswire) +5.93%
Sep-26-24 08:51AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-19-24 02:30AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-17-24 11:22AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-10-24 08:00AM	Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
Sep-03-24 08:00AM	Belite Bio to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Sep-01-24 08:00AM	Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer (GlobeNewswire)
Aug-09-24 09:52PM	BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 (InvestorPlace)
04:30PM	Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-08-24 08:00AM	Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.33%
Aug-05-24 07:10PM	Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-08-24 08:00AM	Belite Bio to Present at the JonesHealthcare Seaside Summit (GlobeNewswire) +6.81%
Jun-12-24 02:55AM	Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan (GlobeNewswire)
May-14-24 08:00AM	Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference (GlobeNewswire)
07:53AM	BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 (InvestorPlace)
05:17AM	Belite Bio's Q1 Loss Narrows (MT Newswires)
May-13-24 09:50PM	Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-08-24 08:00AM	Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 08:15AM	Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant (GlobeNewswire)
08:00AM	Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting (GlobeNewswire)
May-01-24 04:15PM	Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Apr-26-24 06:21AM	Belite Bio Unveils Plan to Offer 651,380 American Depository Shares (MT Newswires)
Apr-25-24 07:15PM	Belite Bio Announces $25 Million Registered Direct Offering (GlobeNewswire)
Apr-10-24 09:55AM	Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect? (Zacks)
Mar-22-24 08:00AM	Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan (GlobeNewswire)
Mar-11-24 10:28PM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire) -12.47%
09:27PM	Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 08:00AM	Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-04-24 08:00AM	Belite Bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-07-24 08:00AM	Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-30-23 08:00AM	Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference (GlobeNewswire) +10.10%
Nov-20-23 08:00AM	Belite Bio to Participate in the BTIG Ophthalmology Day (GlobeNewswire)
Nov-13-23 08:15PM	Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Nov-10-23 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Nov-07-23 08:00AM	Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 04:00PM	Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023 (GlobeNewswire)
08:00AM	Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting (GlobeNewswire)
Nov-01-23 08:35AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts (GlobeNewswire) +5.04%
Oct-31-23 08:35PM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 (GlobeNewswire)
Oct-27-23 08:00AM	Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting (GlobeNewswire)
Aug-21-23 11:12AM	Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why (Zacks)
Aug-08-23 10:17PM	Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Aug-04-23 08:00AM	Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results (GlobeNewswire) +10.63%
Jul-31-23 07:57AM	Is Belite Bio, Inc (NASDAQ:BLTE) Worth US$24.1 Based On Its Intrinsic Value? (Simply Wall St.)
Jul-27-23 05:00PM	Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA (GlobeNewswire) +10.37% +17.27%
Jul-24-23 06:04AM	Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease (GlobeNewswire)
Jun-30-23 04:09PM	Why Shares of Belite Bio Soared This Week (Motley Fool)
May-31-23 12:22PM	Why Shares of Belite Bio Are Slumping Wednesday (Motley Fool) -31.09%
May-30-23 08:49PM	Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants (GlobeNewswire)
04:01PM	Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants (GlobeNewswire)
May-10-23 07:58PM	Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
03:33PM	Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 11:09AM	Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data (GlobeNewswire)
Apr-25-23 04:30PM	Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting (GlobeNewswire)
Apr-11-23 09:00AM	Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1 (GlobeNewswire)
Apr-08-23 09:02AM	We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow (Simply Wall St.)
Mar-31-23 07:03PM	Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
12:57PM	Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results (GlobeNewswire)
Jan-09-23 08:45AM	3 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)

Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Wan Shan Chen	Affiliate	Oct 17 '25	Proposed Sale	121.94	9,550	1,164,500	Oct 17 09:29 AM
Wan Shan Chen	affiliate	Oct 16 '25	Proposed Sale	85.00	1,050	89,250	Oct 16 12:26 PM
Hao-Yuan Chuang	Officer, Director	Oct 13 '25	Proposed Sale	79.77	70,054	5,588,208	Oct 14 03:05 PM
Wan Shan Chen	affiliate	Oct 13 '25	Proposed Sale	80.00	1,050	84,000	Oct 14 12:44 PM
Yu-Hsin Lin	CEO, Chairman	Sep 18 '25	Proposed Sale	73.00	96,950	7,077,350	Sep 18 04:38 PM
Nathan L. Mata	Officer	Aug 21 '25	Proposed Sale	63.42	30,000	1,902,600	Aug 21 05:17 PM
Yu-Hsin Lin	CEO, Chairman	May 21 '25	Proposed Sale	64.81	120,400	7,803,124	May 21 04:30 PM
Nathan Mata	Affiliate	Mar 19 '25	Proposed Sale	67.80	30,166	2,045,126	Mar 19 04:28 PM
Yu-Hsin Lin	CEO, Chairman	Jan 02 '25	Proposed Sale	63.10	162,000	10,222,200	Jan 02 04:44 PM
Hao-Yuan Chuang	Officer, Director	Jan 02 '25	Proposed Sale	63.10	160,000	10,096,000	Jan 02 04:39 PM
Wei-Cheng Liaw	affiliate	Nov 20 '24	Proposed Sale	82.53	5,999	495,097	Nov 20 06:25 PM
Nathan Mata	Affiliate	Nov 19 '24	Proposed Sale	82.34	30,000	2,470,200	Nov 19 06:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLTE

Belite Bio Inc ADR

Upgrade your FINVIZ experience